The FDA authorization of PBM reflects an extensive review of clinical trial data, including safety, efficacy, and the robustness of the study results, all of which support the positive utility of this treatment for patients with dry AMD.
Multiple trials have assessed PBM’s safety and effectiveness. At Month 24, approximately 63.7% of PBM-treated eyes responded with significant vision gain, of which 20% could see approximately two lines better on the standard eye chart. The trial also noted additional benefits, including reduced disease progression and improved quality of life. Further, the treatment was very safe and required nothing invasive, such as injections or surgery.
Photobiomodulation (PBM) is a non-invasive light therapy that uses specific wavelengths of visible and near-infrared light to stimulate cellular function and improve retinal health.
